Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution, and sale of cannabis related products in Canada and internationally. The Company’s segments include Canadian Cannabis, European Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia, and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets.


TSX:ACB - Post by User

Bullboard Posts
Comment by longonMJon May 19, 2019 7:11pm
85 Views
Post# 29759997

RE:Sector reevaluations coming for 2019

RE:Sector reevaluations coming for 2019I highly doubt that Linto would be that far off base as he has been quoted many times in interviews that he anticipates sales of $200M per quarter once full legalization comes into effect.  In fact, he states that Canopy's total sales should hit the $1B mark for their 2020 fiscal year which starts in April 2019.

Just took a look at the consensus estimates for Canopy and it appears that the analysts have them coming in with net sales revenue of $110M, with a bottom range of $85M and a high end of $133M for their 2019 Q4 results due out next month.

I somehow don't believe we should be going with the government numbers to try to calculate sales revenues for the MJ companies.

Mdaw94 wrote: Government numbers starting to show potential nose dive for Canapys sales. This should lead to reevaluations in market caps through out the sector with Aurora emerging as the market leader with sales, profit margins, capacity growth


Bullboard Posts